Treatment of growth hormone deficiency in adults

Hormone Research

Volumn 71, Issue SUPPL. 1, 2009, Pages 116-122

  Johannsson, Gudmundur ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Endocrinology ^*  (Sweden)

Author keywords

Consensus; Growth hormone deficiency; Growth hormone research society

Indexed keywords

ESTROGEN; GROWTH HORMONE; LIOTHYRONINE; PLACEBO; TESTOSTERONE; THYROXINE;

BIOLOGICAL MONITORING; BODY COMPOSITION; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFERENCE PAPER; CRANIOPHARYNGIOMA; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS TUMOR; HYPOPITUITARISM; INCIDENCE; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RISK FACTOR; TREATMENT RESPONSE; TUMOR RECURRENCE;

ADULT; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH DISORDERS; HEALTH PLANNING GUIDELINES; HUMAN GROWTH HORMONE; HUMANS; NEOPLASMS; YOUNG ADULT;

EID: 58649101322     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178052     Document Type: Conference Paper

References (51)

1. Rosén T, Bengtsson B-Å: Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet 1990;336:285-288.
2. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.
3. Nilsson AG, Svensson J, Johannsson G: Management of growth hormone deficiency in adults. Growth Horm IGF Res 2007;17:441-462.
4. Ho KK, 2007 GH Deficiency Consensus Workshop Participants: Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007;157:695-700.
5. Weaver JU, Thaventhiran L, Noonan K, Burrin JM, Taylor NF, Norman MR, Monson JP: The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 1994;41:639-648.
6. Jørgensen JOL, Pedersen SA, Laurberg P, Weeke J, Sakkebæk NE, Christiansen JS: Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxinesubstituted central hypothyroidism. J Clin Endocrinol Metab 1989;69:1127-1132.
7. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK: Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab 2001;281:E1191-E1196.
8. Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK: Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab 2005;90:3989-3994.
9. Johannsson G, Bjarnason R, Bramnert M, Carlsson LMS, Degerblad M, Manhem P, Rosén T, Thorén M, Bengtsson B-Å: The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH binding protein, body mass index, age and gender. J Clin Endocrinol Metab 1996;81:1575-1581.
10. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA: Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997;82:550-555.
11. de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E: Monitoring of growth hormone replacement therapy in adults, based on measurements of serum markers. J Clin Endocrinol Metab 1996;81:1371-1377.
12. Johannsson G, Rosén T, Bengtsson B-Å: Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997;47:571-581.
13. Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP: Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998;83:3913-3919.
14. Colle M, Auzerie J: Discontinuing of growth hormone therapy in growth hormone-deficient patients: assessment of body fat mass using bioelectrical impedance. Horm Res 1993;39:192-196.
15. Johannsson G, Albertsson-Wikland K, Bengtsson B-Å: Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999;84:4516-4524.
16. Rutherford OM, Jones DA, Round JM, Buchanan CR, Preece MA: Changes in skeletal muscle and body composition after discontinuing of growth hormone treatment in growth hormone deficient adults. Clin Endocrinol (Oxf) 1991;34:469-475.
17. Koranyi J, Svensson J, Gotherstrom G, Sunnerhagen KS, Bengtsson B, Johannsson G: Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study. J Clin Endocrinol Metab 2001;86:4693-4699.
18. Attanasio AF, Lamberts SWJ, Matranga AMC, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson B-Å, Strasburger CJ: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997;82:82-88.
19. Wirén L, Johannsson G, Bengtsson B-Å: A prospective investigation of quality of life and psychological well-being following the discontinuation of growth hormone (GH) treatment in adolescent patients who had GH deficiency during their childhood. J Clin Endocrinol Metab 2001;86:3494-3498.
20. Borges O: Isometric and isokinetic knee extension and flexion torque in men and women aged 20-70. Scand J Rehab Med 1989;21:45-53.
21. Larsson L, Grimby G, Karlsson J: Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 1979;46:451-456.
22. Jørgensen JOL, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebæck NE, Christiansen JS: Beneficial effect of growth hormone treatment in GH-deficient adults. Lancet 1989;i:1221-1225.
23. Nelson DA, Simpson PM, Johnson CC, Barondess DA, Kleerekoper M: The accumulation of whole body skeletal mass in third-and fourth-grade children: effects of age, gender, ethnicity, and body composition. Bone 1997;20:73-78.
24. Hulthén L, Bengtsson BÅ, Sunnerhagen KS, Hallberg L, Grimby G, Johannsson G: GH is needed for the maturation of muscle mass and strength in adolescents. J Clin Endocrinol Metab 2001;86:4765-4770.
25. Vahl N, Juul A, Jørgensen JOL, Ørskov H, Skakkebæk NE, Christiansen JS: Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood and adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 2000;85:1874-1881.
26. Norrelund H, Vahl N, Juul A, Møller N, Alberti KG, Skakkebaek NE, Christiansen JS, Jørgensen JO: Continuation of growth hormone (GH) therapy in GH-deficient patients during transition form childhood to adulthood: impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab 2000;85:1912-1917.
27. Carroll PV, Drake WM, Maher KT, Metcalfe K, Shaw NJ, Dunger DB, Cheetham TD, Camacho-Hubner C, Savage MO, Monson JP: Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004;89:3890-3895.
28. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hubner C, Shaw NJ, Dunger DB, Cheetham TD, Savage MO, Monson JP: The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003;88:1658-1663.
29. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, Moshang T, Blum WF, Chipman JJ, Quigley CA, Attanasio AF: Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003;88:4124-4129.
30. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B: Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005;90:3946-3955.
31. Toogood AA, O'Neill PA, Shalet SM: Beyond somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996;81:460-465.
32. Toogood AA, Adams JE, O'Neill PA, Shalet SM: Body composition in growth hormone deficient adults over the age of 60 years. Clin Endocrinol 1996;45:399-405.
33. Franco C, Johannsson G, Bengtsson B-A, Svensson J: Baseline characteristics and effects of growth hormone therapy over two years in younger and older adults with adult onset GH deficiency. J Clin Endocrinol Metab 2006;91:4408-4414.
34. Gotherstrom G, Bengtsson BA, Sunnerhagen KS, Johannsson G, Svensson J: The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clin Endocrinol (Oxf) 2005;62:105-113.
35. Fernholm R, Bramnert M, Hagg E, Hilding A, Baylink D, Mohan S, Thorén M: Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000;85:4104-4112.
36. Toogood AA, Adams JE, O'Neill PA, Shalet SM: Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 1997;82:1462-1466.
37. Elgzyri T, Castenfors J, Hagg E, Backman C, Thorén M, Bramnert M: The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol (Oxf) 2004;61:113-122.
38. Monson J, Abs R, Bengtsson B-Å, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Thorén M, Westberg B, Wilton P, Wuster C: Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database. Clin Endocrinol (Oxf) 2000;53:281-289.
39. Feldt-Rasmussen U, Wilton P, Jonsson P: Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Horm IGF Res 2004;14(suppl A):S51-S58.
40. Monson JP, Bengtsson BA, Abs R, Feldt-Rasmussen U, Wuster C: Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 2000;355:1728-1729.
41. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA: Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355:610-613.
42. Brada M, Rajan B, Traish D, Ashley S, Holmes-Sellors PJ, Nussey S, Uttley D: The longterm efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571-578.
43. Frajese G, Drake WM, Loureiro RA, Evanson J, Coyte D, Wood DF, Grossman AB, Besser GM, Monson JP: Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 2001;86:5172-5175.
44. Karavitaki N, Warner JT, Marland A, Shine B, Ryan F, Arnold J, Turner HE, Wass JA: GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 2006;64:556-560.
45. Buchfelder M, Kann PH, Wuster C, Tuschy U, Saller B, Brabant G, Kleindienst A, Nomikos P: Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol 2007;157:149-156.
46. Jostel A, Mukherjee A, Hulse PA, Shalet SM: Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf) 2005;62:698-705.
47. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J: Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998;49:441-445.
48. Nilsson B, Gustavsson-Kadaka E, Bengtsson BA, Jonsson B: Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000;85:1420-1425.
49. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M: Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005;90:800-804.
50. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA: Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006;91:3494-3498.
51. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL: Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 2002;87:3136-3141.